Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ConvaTec heads higher as City broker upgrades to ‘hold’ ahead of new year

Numis analyst Paul Cuddon thinks the balance between risk and reward is now more fairly balanced
colostomy
Time for ConvaTec to start healing old wounds?

ConvaTec Group PLC (LON:CTEC) edged higher on Wednesday morning after the colostomy bag maker was upgraded by analysts at Numis.

The City broker noted that 2017 – ConvaTec’s first full year since its IPO in late 2016 – had proved to be a “disappointment”, with a slide in margins expected to lead to underlying earnings dipping to US$451mln (2016: US$472.2mln) when the FTSE 250 group reports its full-year results next week.

READ: ConvaTec lowers revenue guidance after supply issues hit third-quarter performance

But analyst Paul Cuddon still feels the company is one of just a handful of players in a “demographically attractive market”.

“In a more aggressive competitive environment we still see risks to ostomy, especially in the US and more broadly to Woundcare given the weakening quarterly trends,” said Cuddon in a research note.

“That said, we are open-minded heading into a new financial year, and over the mid/longer [term] believe a focus on finding further operational efficiencies is key to delivering sustainable growth after several years of flat to declining EBITDA.

“With the shares trading on 13x FY18 EV/EBITDA think the risk/reward is now more fairly balanced and so upgrade to ‘hold’ with our 180p target price maintained.”

READ: ConvaTec's shares gain as full year earnings grow after IPO

The analyst added that he wants to see more innovation or acquisition in the woundcare business and greater efficiency in the ostomy and critical care divisions.

For 2018, Numis is forecasting underlying earnings of US$452.6mln on increased sales of US$1.85bn.

ConvaTec shares gained 3.3% to 197.4p on Wednesday.

View full CTEC profile View Profile

ConvaTec Group PLC Timeline

Related Articles

picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
numerous pills
March 23 2018
Genervon is on the lookout for pharma partners to help advance its GM6 drug, which takes aim at a range of deadly diseases hitting the central nervous system
couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use